MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities
Renalytix (NASDAQ:RNLXY) has partnered with MVP Health Care to expand access to its FDA-approved kidneyintelX.dkd™ test for diabetic kidney disease patients across MVP's Northeast network. The collaboration aims to improve early detection and management of kidney disease in patients with type 2 diabetes.
The partnership will make the innovative diagnostic test available to all MVP customers in New York, including Medicare and Medicaid beneficiaries. The test is recommended by KDIGO, the international clinical guideline organization for kidney disease, and has shown measurable improvements in patient outcomes and quality metrics where implemented.
Renalytix (NASDAQ:RNLXY) ha stretto una collaborazione con MVP Health Care per ampliare l'accesso al suo test kidneyintelX.dkd™ approvato dalla FDA per i pazienti con malattia renale diabetica all'interno della rete MVP nel Nord-Est. L'obiettivo della partnership è migliorare la diagnosi precoce e la gestione della malattia renale nei pazienti con diabete di tipo 2.
La collaborazione renderà disponibile questo innovativo test diagnostico a tutti i clienti MVP nello stato di New York, inclusi i beneficiari di Medicare e Medicaid. Il test è raccomandato da KDIGO, l'organizzazione internazionale che definisce le linee guida cliniche per le malattie renali, e ha dimostrato miglioramenti concreti negli esiti dei pazienti e negli indicatori di qualità dove è stato adottato.
Renalytix (NASDAQ:RNLXY) se ha asociado con MVP Health Care para ampliar el acceso a su prueba kidneyintelX.dkd™ aprobada por la FDA para pacientes con enfermedad renal diabética en la red del noreste de MVP. La colaboración busca mejorar la detección temprana y el manejo de la enfermedad renal en pacientes con diabetes tipo 2.
La asociación hará que esta innovadora prueba diagnóstica esté disponible para todos los clientes de MVP en Nueva York, incluidos los beneficiarios de Medicare y Medicaid. La prueba está recomendada por KDIGO, la organización internacional de guías clínicas para enfermedades renales, y ha demostrado mejoras significativas en los resultados de los pacientes y en los indicadores de calidad donde se ha implementado.
Renalytix (NASDAQ:RNLXY)는 MVP Health Care와 협력하여 MVP의 북동부 네트워크 내 당뇨병성 신장 질환 환자를 위한 FDA 승인 kidneyintelX.dkd™ 검사의 접근성을 확대했습니다. 이번 협력은 제2형 당뇨병 환자의 신장 질환 조기 발견 및 관리 개선을 목표로 합니다.
이 파트너십을 통해 뉴욕에 거주하는 모든 MVP 고객, 메디케어 및 메디케이드 수혜자에게 이 혁신적인 진단 검사가 제공됩니다. 이 검사는 신장 질환 국제 임상 지침 기관인 KDIGO에서 권장하며, 도입된 곳에서 환자 결과와 품질 지표가 눈에 띄게 개선된 것으로 나타났습니다.
Renalytix (NASDAQ:RNLXY) s'est associé à MVP Health Care pour étendre l'accès à son test kidneyintelX.dkd™ approuvé par la FDA destiné aux patients atteints de maladie rénale diabétique dans le réseau nord-est de MVP. Cette collaboration vise à améliorer la détection précoce et la prise en charge de la maladie rénale chez les patients atteints de diabète de type 2.
Ce partenariat rendra ce test diagnostique innovant disponible pour tous les clients de MVP dans l'État de New York, y compris les bénéficiaires de Medicare et Medicaid. Le test est recommandé par KDIGO, l'organisation internationale des directives cliniques pour les maladies rénales, et a démontré des améliorations mesurables des résultats pour les patients et des indicateurs de qualité là où il a été mis en œuvre.
Renalytix (NASDAQ:RNLXY) hat eine Partnerschaft mit MVP Health Care geschlossen, um den Zugang zu seinem FDA-zugelassenen kidneyintelX.dkd™-Test für Patienten mit diabetischer Nierenerkrankung im nordöstlichen Netzwerk von MVP zu erweitern. Ziel der Zusammenarbeit ist die Verbesserung der Früherkennung und Behandlung von Nierenerkrankungen bei Patienten mit Typ-2-Diabetes.
Die Partnerschaft wird den innovativen Diagnosetest allen MVP-Kunden in New York, einschließlich Medicare- und Medicaid-Empfängern, zugänglich machen. Der Test wird von KDIGO, der internationalen klinischen Leitlinienorganisation für Nierenerkrankungen, empfohlen und hat dort, wo er eingesetzt wird, messbare Verbesserungen bei Patientenergebnissen und Qualitätskennzahlen gezeigt.
- FDA-approved kidneyintelX.dkd test will be available to all MVP customers, including Medicare/Medicaid beneficiaries
- Partnership expands market reach in the Northeast region
- Test demonstrates measurable improvements in patient outcomes and HEDIS measures
- Endorsement by KDIGO (international clinical guideline organization)
- None.
New partnership expands access to prognostic testing for people with diabetic kidney disease, helping improve lives and reduce health disparities.
Through this partnership, MVP Health Care and Renalytix will collaborate with physician groups across MVP's network to introduce and implement the kidneyintelX.dkd™ FDA-approved test. By making this innovative technology more accessible to providers and patients, the partnership supports earlier intervention, more personalized care plans, and healthier, more independent lives.
"At MVP Health Care, we are committed to delivering innovative, affordable solutions that improve access to care and support better health for our members," said MVP Health Care's President, Dr. Richard Dal Col. "This partnership with Renalytix reflects our mission to empower both providers and patients with the tools they need to make informed, proactive decisions about their health care journey. For our customers living with type 2 diabetes and CKD, this means earlier insights, more personalized support, and a better path forward."
The kidneyintelX.dkd™ test will be available to all MVP customers in
"Forward-thinking in its approach, MVP Health Care is bringing together the right partners to address the growing and costly CKD epidemic," said James McCullough, CEO of Renalytix. "Where kidneyintelX.dkd is in use, we are seeing measurable improvements in patient outcomes and quality metrics, including HEDIS measures for blood pressure and HbA1c control in high-risk populations. We're proud to work alongside MVP to make this level of care more widely available."
To learn more about Renalytix, visit renalytix.com, and for information about the kidneyintelX.dkd test, visit kidneyintelx.com.
About Renalytix
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in
About MVP Health Care
MVP Health Care is a nationally recognized, not-for-profit health insurer caring for members in
For further information, please contact:
Renalytix plc | |
View original content:https://www.prnewswire.com/news-releases/mvp-health-care-and-renalytix-partner-to-bring-life-changing-kidney-disease-testing-to-local-communities-302509197.html
SOURCE Renalytix plc
FAQ
What is the new partnership between Renalytix (RNLXY) and MVP Health Care?
Who will have access to Renalytix's kidneyintelX.dkd test through the MVP Health Care partnership?
What benefits does the Renalytix (RNLXY) kidneyintelX.dkd test provide?
Is the Renalytix kidneyintelX.dkd test FDA approved?
